top of page
  • Writer's pictureLaurent DECORY

Combining checkpoint inhibitors improves cancer reduction and survival

Updated: May 24, 2020

Checkpoint inhibitors against PD-1, PD-L1, CTLA-4 are dramatically improving cancer treatment in defined patient sub-sets. Combining them together and with chemo seems even more effective, as shown by coming Asco communications from Roche/Genentech and Bristol Myers Squibb Optimizing product portfolio and launch strategy is among BlueJet Consulting areas of expertise. Contact us for a free diagnosis. #postcovid19 #Oncology Continue reading

4 views0 comments


bottom of page